A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (MONARCH plus)
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]Eli Lilly and Company[2]Instituto do Câncer - Hospital Mãe de Deus Center/AESC Porto Alegre, Rio Grande Do Sul, Brazil, 90110-270[3]Fundação PIO XII Barretos, Sao Paulo, Brazil, 14784700[4]Hospital de Base Fac de Medicina de Sao Jose do Rio Preto Sao Jose Rio Preto, Sao Paulo, Brazil, 15090-000[5]Instituto do Cancer do Estado de Sao Paulo - ICESP Sao Paulo, Brazil, 01246000[6]Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária São Paulo, Brazil, 01317-000[7]Afflilated Hospital of Bengbu Medical College Bengbu, Anhui, China, 233004[8]The 307th Hospital of Chinese People's Liberation Army Beijing, Beijing, China, 100071[9]Fujian Provincial Cancer hospital Fuzhou, Fujian, China, 350014[10]Fujian Province Hospital Fuzhou, Fujian, China, 350025[11]Affiliated Cancer Hospital of Guangxi Medical University Nan Ning, Guang XI, China, 530000[12]Guangdong Province People's Hospital Guangzhou, Guangdong, China, 510080[13]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510120[14]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050011河北医科大学第四医院[15]Harbin Medical University Caner Hospital Harbin, Heilongjiang, China, 150081[16]Henan Cancer Hospital Zhengzhou, Henan, China, 450008[17]Wu Han Tongji Hospital Wuhan City, Hubei, China, 430030[18]Wuhan Union (Xiehe) Hospital Wuhan, Hubei, China, 430022[19]Hu Bei Cancer Hospital Wuhan, Hubei, China, 430079[20]Hunan Province Tumor Hospital Changsha, Hunan, China, 410013[21]Jilin Province Tumor Hospital Chang Chun, Ji Lin, China, 130012[22]Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med Nanjing, Jiangsu, China, 210008[23]Jiangsu Province Cancer Hospital Nanjing, Jiangsu, China, 210009[24]Dalian Med. Univ. No 2 Affiliate Hospital Dalian, Liao Ning, China, 116023[25]Liaoning Cander Hospital&Institute Shenyang, Liaoning, China, 100042[26]The First Hospital of China Medical University Shenyang, Liaoning, China, 110001[27]The First Affiliated Hospital with Nanjing Medical Universit Nanjing, Nanjing, China, 210029[28]First Affiliated Hospital of Medical College, Xi'an Jiaotong Xi'an, Shaanxi, China, 710061[29]Zhejiang Cancer Hospital Hang Zhou, Zhejiang, China, 310022[30]Second Affiliate Hospital of Zhejiang Medical University Hangzhou, Zhejiang, China, 310009[31]Beijing Tumor Hospital Beijing, China, 100142[32]Shanghai Tumor Hospital Shanghai, China, 200030[33]Shanghai First People's Hospital Shanghai, China, 200080[34]Tianjin Medical University Cancer Institute & Hospital Tianjin, China, 300060[35]Dr. B. L. Kapur Memorial Hospital New Delhi, Delhi, India, 110005[36]The Gujarat Cancer & Research Institute (GCRI) Ahmedabad, Gujarat, India, 380016[37]M S Ramaiah Medical College Hospital Bangalore, Karnataka, India, 560054[38]Healthcare Global Enterprises Limited (HCG) Bangalore, Karnataka, India, 560095[39]Tata Memorial Hospital Mumbai, Maharashtra, India, 400 012[40]Jehangir Hospital Pune, Maharashtra, India, 411001[41]Christian Medical College and Hospital Vellore, Tamil Nadu, India, 632 004[42]Medica Superspecialty Hospital Kolkata, West Bengal, India, 700099[43]The Medical Oncology Centre of Rosebank Johannesburg, Gauteng, South Africa, 2196[44]Eastleigh Breast Care Center Pretoria, Gauteng, South Africa, 0081[45]Sandton Oncology Centre Johannesburg, South Africa, 2196[46]Hospital de Caridade Ijui Ijui, Rio Grande Do Sul, Brazil, 98700 000
The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.
